Trial Profile

An open-label, multi-centre Phase Ib study of the safety and tolerability of IV infused PG545 in combination with nivolumab in patients with advanced solid tumours with an expansion cohort in patients with metastatic pancreatic cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; Pixatimod (Primary)
Indications Adrenocortical carcinoma; Colorectal cancer; Endometrial cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer; Uterine cancer
Focus Adverse reactions

16 Jun 2021 Planned number of patients changed from 50 to 62.
16 Jun 2021 Status changed from recruiting to completed.
16 Nov 2018 Preliminary results (n=9 data cut off: 19, June 2018) presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com